一系列共价,细胞活性Bfl-1抑制剂的基于结构的优化
Simon C C Lucas1, J Henry Blackwell1, Ulf Börjesson2
1Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Journal of medicinal chemistry
|September 18, 2024
概括
研究人员开发了一种针对Bfl-1的新型共价抑制剂,该蛋白质与癌症存活率和耐药性有关. 这种优化的化合物显示出显著的功效和有希望的体内疗效,用于癌症治疗.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 包括Bfl-1在内的Bcl-2家族蛋白调节细胞亡,对癌细胞存活至关重要.
- Bfl-1有助于抵抗venetoclax疗法,这是一个向的癌症治疗.
- 在Bfl-1的BH3结合部位中的独特的氨酸残留物为有针对性的共价抑制提供了机会.
研究的目的:
- 为了优化一个类似于的击中一个强大的共价细胞工具,准Bfl-1.
- 开发一种基于结构的设计策略,用于制造有效的Bfl-1抑制剂.
- 评估优化化合物的生物化学效能,细胞活性和体内特征.
主要方法:
- 基于结构的药物设计由X射线碎片查提供信息.
- 优化与谷氨酸残留物 (Glu78) 和一个神秘的结合口袋的相互作用.
- 生物化学试验以确定结合动力学 (ki/Ki).
- 细胞测试以测量酶激活和目标参与.
主要成果:
- 在生化功效方面取得了1000倍的改善.
- 开发了一种具有ki/Ki 4600 M-1 s-1 的化合物.
- 在细胞测定中显示<1μM的酶激活,并证实了细胞点的参与.
- 优化的化合物表现出有利的物理化学特性和有前途的体内特征.
结论:
- 基于结构的设计有效优化了向Bfl-1的共价抑制剂.
- 开发的化合物显示出高强度和细胞活性,表明治疗潜力.
- 这种方法为克服癌症中Bfl-1-介导的耐药性提供了一个有希望的策略.
更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.3K
08:35Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
Published on: May 29, 2021
5.1K
相关概念视频
Noncovalent Attractions in Biomolecules
49.4K
Noncovalent attractions are associations within and between molecules that influence the shape and structural stability of complexes. These interactions differ from covalent bonding in that they do not involve sharing of electrons.
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
49.4K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Ligand Binding Sites
12.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.8K
Conserved Binding Sites
4.2K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.2K
Structure-Activity Relationships and Drug Design
676
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
676
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
